Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Cancer Medicine|July 6, 2019
Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodiesDominique Rosillon, Laurence Baril, Maria Rowena Del Rosario-Raymundo, et al.
The Journal of Infectious Diseases|December 9, 2022
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of AgeJavier Díez-Domingo, Xavier Sáez-Llorens, Miguel A Rodriguez-Weber, et al.
Lancet (London, England)|September 6, 2014
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyS Rachel Skinner, Anne Szarewski, Barbara Romanowski, et al.
The Journal of Infectious Diseases|October 5, 2013
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observationAnne Szarewski, S Rachel Skinner, Suzanne M Garland, et al.
Clinical and Vaccine Immunology : CVI|December 26, 2014
Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNAFrank Struyf, Brigitte Colau, Cosette M Wheeler, et al.
The Lancet. Infectious Diseases|July 5, 2016
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyCosette M Wheeler, S Rachel Skinner, M Rowena Del Rosario-Raymundo, et al.
Contemporary Clinical Trials|March 7, 2019
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki diseaseSamantha C Roberts, Sonia Jain, Adriana H Tremoulet, et al.
The Lancet. Oncology|June 14, 2015
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA TrialsAimée R Kreimer, Frank Struyf, Maria Rowena Del Rosario-Raymundo, et al.
Pageof 7